Background/Aims: Dipeptidyl peptidase-4 (DPP-4) inhibitors have pleiotropic effects on cardiovascular protection beyond the antidiabetic property. However, it remains unknown that the impact of one DPP-4 inhibitor sitagliptin on the survival of mesenchymal stem cells (MSCs) in hypoxia and serum deprivation (H/SD) environment. Methods: The apoptosis and autophagy of MSCs were analyzed in different concentrations of sitagliptin under H/SD condition. For later studies, we tested the relationship between anti-apoptotic and anti-autophagic effects of sitagliptin. The level of cell apoptosis was analyzed by Annexin V-FITC/PI staining, western blot of Beclin 1 and light chain 3 protein, and transmission electron microscopy. Results: We demonstrated that sitagliptin attenuated hypoxia-induced apoptosis and autophagy of MSCs. Furthermore, sitagliptin regulated cell autophagy by Bcl-2/ Beclin 1 pathway in H/SD condition. Conclusions: This study provides insight into the utility of the DPP-4 inhibitor sitagliptin for MSCs transplantation in the ischemic microenvironment that extends its antidiabetic property.
Introduction
Acute myocardial infarction is still a leading cause of morbidity and mortality worldwide. Many therapeutic strategies of pharmacologic intervention, percutaneous and keep the viable myocardium working. In recent years, mesenchymal stem cell (MSC) transplantation has been a promising therapy strategy for cardiac repair after myocardium infarction. However, low survival of MSCs in the ischemic microenvironment limits clinical application. Therefore, increasing the survival of MSCs in ischemic microenvironment seems to be important.
Currently, the dipeptidyl peptidase-4 (DPP-4) inhibitors, a new class of oral antihyperglycemic agents, were found to have pleiotropic effects on cardiovascular protection beyond their antidiabetic property [1, 2] . A previous study showed that the DPP-4 inhibitor sitagliptin upregulated the expression of the myocardial prosurvival kinase AKT and improved cardiac functional recovery after ischemia/reperfusion injury [3] . In addition, sitagliptin could reduce myocardial infarct size by cAMP-dependent PKA activation [4] . Systemic pretreatment with the DPP-4 inhibitor enhanced MSCs recruitment into ischemic myocardium, thereby leading to improve local vascularity and reverse myocardial remodeling [5] . Recently, it was showed that sitagliptin increased the amount of MSCs in the circulation and cardiac homing of bone-marrow derived stem cells [6] . However, the impact of the DPP-4 inhibitor sitagliptin on the survival of MSCs in H/SD condition remains unclear.
In the past few decades, the relationship between apoptosis and autophagy-related known that both of them are important in the normal physiological and pathological state.
There is a crosstalk between apoptosis and autophagy complex in nature, and sometimes contradictory, which is critical to the overall fate of the cells [7] . Autophagy can provide energy and metabolic precursors and alleviate stress by removal of damaged proteins and organelles under nutrient-limiting conditions [8, 9] . Paradoxically, prolonged persistent autophagy as a stress response could lead to cell death [10] . Thus, autophagy can either protect cells or promote cell death, depending on the cellular and environmental context [7, 11] . Despite the marked differences between apoptosis and autophagy, their regulation is intimately connected [10] . The same regulator Bcl-2, an anti-apoptotic protein, has been shown to reduce the pro-autophagic activity of Beclin 1 [12, 13] by the mechanism that Bcl-2 interferes with the functions of Beclin 1 [14] . The effect of sitagliptin on apoptosis and autophagy of MSCs in H/SD condition will be studied in our experiment.
autophagy in H/SD condition. Moreover, we investigated the relationship between apoptosis and autophagy in sitagliptin-induced protective effects.
Materials and Methods

Cell culture and treatments
MSCs were isolated from male Sprague-Dawley rats weighing 60-80g. Isolation of rat MSCs was 2 protocol. Nonadherent hematopoietic cells decreased with consecutive passages. The passage 3 cells were used in each experiment.
experiment. Previous studies showed that the early apoptosis and autophagy of MSCs induced by H/SD peaked at 6 hour [15, 16], so we adopted H/SD for 6 hours as the time point to observe the effects of sitagliptin on MSCs. The cells were washed in PBS and exposed to different concentrations of sitagliptin the medium was measured by an anaerobic indicator (Bio-Mrieux). 
Detection of autophagosome by transmission electron microscopy
To further clarify the effects of sitagliptin on cell autophagy, transmission electron microscopy, the , being washed with PBS, cells were then dehydrated by a serial gradient ethanol and then embedded in
Results
Sitagliptin reduced apoptosis of MSCs under H/SD condition
The MSCs were exposed to the H/SD condition with different concentrations of survival than untreated MSCs in a dose-dependent manner. Meanwhile, we analyzed the Bax and Bcl-2 proteins by western blot to identify the anti-apoptotic effect of sitagliptin. Protein expression of Bcl-2 was obviously upregulated, which reached a maximum in 10
Sitagliptin reduced autophagy of MSCs under H/SD condition
To determine whether sitagliptin was able to modulate autophagy of MSCs, we treated 
Discussion
In the present study, we found that sitagliptin attenuated hypoxia-induced apoptosis and autophagy of MSCs. Interestingly, sitagliptin regulated cell autophagy by Bcl-2/Beclin 1 pathway in H/SD condition. These results provide insight into the utility of sitagliptin for MSCs transplantation in the ischemic microenvironment that beyond its antidiabetic property.
of MSCs when they were transplanted into myocardial necrosis area. It is demonstrated that many drugs such as statins or trimetazidine can protect MSCs against H/SD [16, 17]. Moreover, the factors released by of MSCs could protect endothelial cells from serum deprivation [18] . DPP-4 inhibitors are a newer class of oral anti-hyperglycemic agents with inhibitors are demonstrated to mediate pleiotropic effects in cardiovascular protection. DPP-4 inhibitors could decrease myocardial infarct size, stabilize the cardiac electrophysiological state, reduce ischemia/reperfusion injury, and prevent left ventricular remodeling following myocardial infarction [21] [22] [23] . However, it is unclear that whether sitagliptin could inhibit H/SD-induced apoptosis and autophagy of MSCs. in vitro, which is opposite to the study of Ye et al. [4] . Although many evidences indicated that , treatment with sitagliptin in H/SD condition (data not shown). It might be that the protective mechanisms of sitagliptin for MSCs are different from those for the cardiomyocytes. In
The p62 level of MSCs treated by sitagliptin was increased in both 3 hours and 6 hours of H/SD condition, suggesting that autophagy inhibition by sitagliptin was associated with cell sitagliptin.
However, sitagliptin did not further affect cell autophagy when the apoptotic pathways apoptosis of sitagliptin-treated MSCs, suggesting that sitagliptin regulated cell autophagy by some important molecules in apoptotic pathway. That is to say, autophagy inhibition by sitagliptin is secondary to its anti-apoptotic effects. Autophagy could serve as a pro-survival stress response in many settings. However, the role of autophagy in modulating cell death is highly dependent on the cellular context and its extent. In six hours of H/SD, the cells were put in continuously decreasing oxygen levels until anoxia. Persistent autophagy responded to excessive stress. Autophagy may promote cell death through excessive self-digestion and autophagy was the downstream consequences of anti-apoptotic effects of sitagliptin, which further increased cell survival in H/SD condition. The relative amount of Bcl-2 and Beclin 1 complexed to each other within a cell determines the level of autophagy and autophagic cell death. The interaction between endogenous Bcl-2 and Beclin 1 is regulated by nutrient conditions. Bcl-2 binding to Beclin 1 is minimal in nutrient deprivation [13] , and the level of cell autophagy is raised. In addition, Beclin 1 could promote cell autophagy [35] . And cells with reduced Beclin 1 expression exhibited reduced autophagic activity [36, 37] . Taken together, these results jointly suggested that autophagy could be regulated by sitagliptin through Bcl-2/ Beclin 1 pathway in H/SD condition. In summary, sitagliptin could attenuate H/SD-induced apoptosis and autophagy of
MSCs by Bcl-2/ Beclin 1 pathway in H/SD condition.
associate with their subcellular localization [13, 38] . However, we did not distinguish models. These issues will be resolved in future experiments.
